{"id":8591,"date":"2025-09-13T14:55:08","date_gmt":"2025-09-13T11:55:08","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8591"},"modified":"2025-09-13T14:55:08","modified_gmt":"2025-09-13T11:55:08","slug":"arrhythmia-management-in-pregnancy-hrs-consensus-2023","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/arrhythmia-management-in-pregnancy-hrs-consensus-2023\/","title":{"rendered":"Arrhythmia Management in Pregnancy \u2013 HRS Consensus 2023"},"content":{"rendered":"
Arrhythmia Management in Pregnancy \u2013 HRS Consensus 2023<\/div>\n
<\/div>\n
Source: ESC Guidelines on CVD in Pregnancy (ESC Congress, Aug 30, 2025) \u2013 complementing HRS Consensus on Arrhythmias in Pregnancy (Sept 2023).<\/div>\n
<\/div>\n
1. Why Important<\/span><\/div>\n
\u2022 First unified, evidence-based statement for arrhythmias in pregnancy.<\/span><\/div>\n
\u2022 Multidisciplinary: cardiology, EP, obstetrics, neonatology, genetics.<\/span><\/div>\n
\u2022 Provides recommendations, classes, and levels of evidence.<\/span><\/div>\n
<\/div>\n
2. Common Arrhythmias<\/span><\/div>\n
\u2022 Palpitations frequent; often benign (sinus tachycardia, PACs).<\/span><\/div>\n
\u2022 SVT most common clinically significant arrhythmia.<\/span><\/div>\n
\u2022 VT\/VF or AV block rare; usually with structural\/congenital disease.<\/span><\/div>\n
<\/div>\n
3. Diagnostic Approach<\/span><\/div>\n
\u2022 History, physical exam, 12-lead ECG, targeted labs (anemia, thyroid, electrolytes).<\/span><\/div>\n
\u2022 Holter or event monitor if recurrent; implantable monitor if persistent suspicion.<\/span><\/div>\n
\u2022 EPS (Electrophysiology Study) not first-line.<\/span><\/div>\n
<\/div>\n
4. Atrial Fibrillation in Pregnancy<\/span><\/div>\n
\u2022 Unstable: Cardioversion safe (same energy as non-pregnant).<\/span><\/div>\n
\u2022 Stable: IV beta-blockers first line \u2192 then calcium channel blockers or digoxin.<\/span><\/div>\n
\u2022 Class IIa: flecainide or ibutilide if others fail.<\/span><\/div>\n
\u2022 Anticoagulation:<\/span><\/div>\n
\u2022 Guided by CHA\u2082DS\u2082-VASc (not validated in pregnancy but still used).<\/span><\/div>\n
\u2022 DOACs contraindicated in pregnancy & breastfeeding.<\/span><\/div>\n
\u2022 Heparin or warfarin follow prosthetic\/mechanical valve guidelines.<\/span><\/div>\n
<\/div>\n
5. Invasive Procedures<\/span><\/div>\n
\u2022 Catheter ablation or device implantation possible with 3D mapping, minimal radiation.<\/span><\/div>\n
\u2022 Avoid \u201clead apron on abdomen\u201d (increases scatter dose).<\/span><\/div>\n
<\/div>\n
6. Postpartum & Lactation<\/span><\/div>\n
\u2022 Drugs crossing breast milk: digoxin, propranolol, metoprolol, verapamil.<\/span><\/div>\n
\u2022 Safer alternatives: carvedilol, esmolol, procainamide, diltiazem, flecainide, sotalol.<\/span><\/div>\n
\u2022 Avoid amiodarone if possible.<\/span><\/div>\n
<\/div>\n
7. Inherited Arrhythmia Syndromes<\/span><\/div>\n
\u2022 Long QT: continue beta-blockers (nadolol\/propranolol, caution in lactation).<\/span><\/div>\n
\u2022 Brugada: avoid fever, avoid QT-prolonging drugs.<\/span><\/div>\n
\u2022 CPVT (Catecholaminergic Polymorphic Ventricular Tachycardia): rare stress\/exercise-induced polymorphic VT \u2192 treat with beta-blockers \u00b1 flecainide; sometimes sympathectomy or ICD.<\/span><\/div>\n
<\/div>\n
8. Anticoagulation in Pregnancy \u2013 Key Clarifications<\/span><\/div>\n
\u2022 Warfarin:<\/span><\/div>\n
\u2022 Most effective for mechanical valves.<\/span><\/div>\n
\u2022 Risk of teratogenicity, especially (first trimester).<\/span><\/div>\n
\u2022 LMWH (Low-Molecular-Weight Heparin):<\/span><\/div>\n
\u2022 Used in first trimester to reduce fetal risk.<\/span><\/div>\n
\u2022 Transition back to warfarin in 2nd trimester if dose \u22645 mg\/day and INR monitoring available.<\/span><\/div>\n
\u2022 Near delivery (week 36\u201337) \u2192 switch again to LMWH or UFH for easier management at labor.<\/span><\/div>\n
\u2022 Safe for fetus (does not cross placenta).<\/span><\/div>\n
\u2022 LMWH (Low-Molecular-Weight Heparin): Requires anti-Xa monitoring (target peak 0.8\u20131.2 IU\/mL, 4\u20136h post-dose).<\/span><\/div>\n
\u2022 Frequency:weekly or(every 1\u20132 weeks if stable).<\/span><\/div>\n
\u2022 Without monitoring \u2192 unsafe (risk of maternal valve thrombosis).<\/span><\/div>\n
\u2022 UFH (Unfractionated Heparin):<\/span><\/div>\n
\u2022 Alternative if LMWH monitoring not available.<\/span><\/div>\n
\u2022 Monitor aPTT every 2\u20133 days until stable, then regularly.<\/span><\/div>\n
\u2022 Target: 1.5\u20132.5 \u00d7 control.<\/span><\/div>\n
\u2022 Less convenient (multiple daily injections, frequent labs).<\/span><\/div>\n
\u2022 Warfarin:<\/span><\/div>\n
\u2022 If anti-Xa or aPTT monitoring not available \u2192 warfarin is most reliable despite fetal risks.<\/span><\/div>\n
\u2022 Decision based on gestational age + shared decision-making.<\/span><\/div>\n
\u2022 DOACs:<\/span><\/div>\n
\u2022 Strictly contraindicated in pregnancy and lactation.<\/span><\/div>\n
<\/div>\n
9. Syncope in Pregnancy<\/span><\/div>\n
\u2022 Occurs in ~1%.<\/span><\/div>\n
\u2022 Often vasovagal or orthostatic in late pregnancy (uterine compression of IVC).<\/span><\/div>\n
\u2022 Workup: history, exam, ECG, echo, monitoring.<\/span><\/div>\n
\u2022 EPS not indicated if exam and imaging normal.<\/span><\/div>\n
<\/div>\n
10. Key Messages<\/span><\/div>\n
<\/div>\n
\u2022 Most arrhythmias in pregnancy are benign.<\/span><\/div>\n
\u2022 When intervention needed: cardioversion and beta-blockers are safe.<\/span><\/div>\n
\u2022 Anticoagulation follows mechanical valve rules (warfarin or LMWH with monitoring).<\/span><\/div>\n
\u2022 DOACs are contraindicated.<\/span><\/div>\n
\u2022 Shared decision-making is essential: care must balance maternal and fetal safety.<\/span><\/div>\n
<\/div>\n
https:\/\/www.medscape.com\/viewarticle\/993276<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Arrhythmia Management in Pregnancy \u2013 HRS Consensus 2023 Source: ESC Guidelines on CVD in Pregnancy (ESC Congress, Aug 30, 2025) \u2013 complementing HRS Consensus on Arrhythmias in Pregnancy (Sept 2023). 1. Why Important \u2022 First unified, evidence-based statement for arrhythmias in pregnancy. \u2022 Multidisciplinary: cardiology, EP, obstetrics, neonatology, genetics. \u2022 Provides recommendations, classes, and levels […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8591","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8591"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8591\/revisions"}],"predecessor-version":[{"id":8592,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8591\/revisions\/8592"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}